REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ:
CLGN) a regenerative medicine company, today announced its
development program of an antiviral agent for potential treatment
of COVID-19 patients. In-vitro early results of CollPlant's
formulations showed significant inhibition of avian coronavirus
infectivity. CollPlant's formulations designed for the potential
treatment of COVID-19 patients are based on CollPlant's proprietary
recombinant human type I collagen (rhCollagen) imbedded with silver
nanoparticles (AgNP).
The anti-viral treatment concept was evaluated in-vitro using an
avian coronavirus, a model of the human coronavirus SARS-COV-2,
grown on epithelial cells. The potential efficacy was assessed by
the ability of the formulations to protect the epithelial cells
from lethal doses of the virus. The results show significant
reduction in infectivity of the model virus by treatment with the
rhCollagen-AgNP complexes. Further studies are ongoing to optimize
the formulations and doses. CollPlant intends to develop an
anti-viral inhalation formulation to limit the spread of
coronavirus in the upper and lower respiratory systems.
"We are very pleased with the initial results from our COVID-19
program which demonstrate a significant reduction in coronavirus
infectivity with CollPlant's antiviral rhCollagen-AgNP
complex. While still in an early stage of development, by
targeting the viral load CollPlant's formulations have the
potential to assist the body's immune system to combat the viral
infection, reduce transmission rates between people, reduce the
percentage of patients who need to be treated in critical care
settings, and shorten hospitalization time," stated Yehiel Tal, Chief Executive Officer of
CollPlant. "Early treatment of the disease can prevent COVID-19
patients from developing more severe symptoms. With the pandemic
inflicting a high human and financial toll, an available treatment
can benefit millions worldwide and allow rapid recovery of social
and economic activity while reducing the probability for new
waves of infection."
About CollPlant
CollPlant is a regenerative medicine company focused on 3D
bioprinting of tissues and organs, and medical aesthetics. Our
products are based on our rhCollagen (recombinant human collagen)
that is produced with CollPlant's proprietary plant based genetic
engineering technology.
Our products address indications for the diverse fields of
tissue repair, aesthetics and organ manufacturing, and, we believe,
are ushering in a new era in regenerative and aesthetic
medicine.
Our flagship rhCollagen BioInk product line is ideal for 3D
bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans.
For more information about CollPlant,
visit http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the outbreak of the
COVID-19 pandemic; the Company's expectations regarding the timing
and cost of commencing clinical trials with respect to tissues and
organs which are based on its rhCollagen based BioInk and products
for medical aesthetics; the Company's ability to successfully
develop a formulation as a treatment for COVID-19 and to
successfully commercialize any product in that indication; the
Company's ability to obtain favorable pre-clinical and clinical
trial results; regulatory action with respect to rhCollagen based
BioInk and medical aesthetics products including but not limited to
acceptance of an application for marketing authorization review and
approval of such application, and, if approved, the scope of the
approved indication and labeling; commercial success and market
acceptance of the Company's rhCollagen based products in 3D
Bioprinting and medical aesthetics; the Company's ability to
establish sales and marketing capabilities or enter into agreements
with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
View original
content:http://www.prnewswire.com/news-releases/collplant-announces-early-development-program-of-antiviral-agent-for-potential-treatment-of-covid-19-patients-301169551.html
SOURCE CollPlant